XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARIZES THE ALLOCATION OF ESTIMATED FAIR VALUES (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Business Acquisition [Line Items]    
Due from related party $ 108,296  
Inventories, net 18,115,423  
Other current assets, net 224,522  
Right of use assets 1,127,130  
Long-term investments and other non-current assets 166,107  
Other payables and other current liabilities (2,503,607)  
Operating lease liabilities (1,013,492)  
Total purchase price for acquisition, net of US$621,979 of cash 16,224,379  
Goodwill 6,574,743
Changzhou Biowin Pharmaceutical Co Ltd [Member]    
Business Acquisition [Line Items]    
Inventories, net 784,336  
Other current assets, net 49,979  
Total purchase price for acquisition, net of US$621,979 of cash 11,475,021  
Accounts receivable, net 807,771  
Property and equipment, net 138,252  
Intangible assets 12,683,656  
Operating lease right-of-use assets 173,831  
Goodwill 6,574,743  
Deferred tax assets, net 346,523  
Short-term bank loans (1,594,596)  
Accounts payable (349,989)  
Deferred revenue (407,437)  
Other current liabilities (446,729)  
Operating lease liabilities - non-current (45,730)  
Deferred tax liabilities (1,937,804)  
Non-controlling interest $ (5,301,785)